At a time when there is pressure on how large US companies are making domestic or overseas acquisitions are coming under more scrutiny, Pfizer Inc. (PFE) announced on Monday that the Federal Trade Commission has terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 over Pfizer’s pending acquisition of Hospira (HSP). While this sounds like an auto-approval, the conditions to the approval are that Pfizer must divest four U.S. sterile injectable assets. These include Acetylcysteine, Clindamycin... More